Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.351
Peer-review started: June 2, 2018
First decision: July 10, 2018
Revised: July 17, 2018
Accepted: August 26, 2018
Article in press: August 26, 2018
Published online: October 15, 2018
Rectal cancer is one of the most common form of cancer in both men and women. Gene expression profiling for predicting the response and long-term prognosis of malignancies has been reported in recent decades. Vascular endothelial growth factor (VEGF) and class III β-tubulin (TUBB3) have been reported to play a vital role in cancer progression. However, few studies focused on their role in rectal cancer.
We try to explore the potential prognostic value of VEGFR1 and TUBB3 for long-term survival in non-metastatic rectal cancer.
A total of 75 patients diagnosed with primary rectal adenocarcinoma without metastases were retrospectively analyzed.
Multiplex branched DNA liquidchip technology was applied to detected mRNA expressions of VEGFR1 and TUBB3. The cutoff point of mRNA expression was determined by Cutoff Founder.
VEGFR1 expression was positively correlated to TUBB3. Patients with both low expression of TUBB3 and VEGFR1 presented a better overall survival (OS). In addition, VEGFR1 and lymph node metastasis had potential as prognostic factors for OS in non-metastatic rectal cancer patients, and the combination of them showed a favorable prognostic value.
We confirmed that the increased expression of VEGFR1 and TUBB3 might be negatively correlated with long-term prognosis of non-metastatic rectal cancer. Furthermore, VEGFR1 expression and lymph node metastasis affected the survival independently, as well as synergistically. These results might provide additional prognostic information compared to the conventional tumor histopathological factors.
VEGFR1 has the potential to contribute to decision making regarding individual treatment in rectal cancer. A larger sample size and additional mRNA expression data are warranted to establish a superior prognosis model.